PHARVARIS
Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.
PHARVARIS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2015-01-01
Address:
Zug, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.pharvaris.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
162.29 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Arctoris
Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Core Biogenesis
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
MiNA Therapeutics
MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
OMass Technologies
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
Syros Pharmaceuticals
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Pharvaris
Venrock
Venrock investment in Series C - Pharvaris
venBio Partners
venBio Partners investment in Series C - Pharvaris
General Atlantic
General Atlantic investment in Series C - Pharvaris
Viking Global Investors
Viking Global Investors investment in Series C - Pharvaris
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series C - Pharvaris
Foresite Capital
Foresite Capital investment in Series C - Pharvaris
Venrock
Venrock investment in Series B - Pharvaris
Foresite Capital
Foresite Capital investment in Series B - Pharvaris
Kurma Partners
Kurma Partners investment in Series B - Pharvaris
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-11 | Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer |
Official Site Inspections
http://www.pharvaris.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.54 K
- Host name: cloudproxy10157.sucuri.net
- IP address: 192.124.249.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Pharvaris"
About Us - Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target 1,2,3 with novel, oral small molecules, the Pharvaris team is advancing …See details»
Pharvaris | Late-Stage Biopharma Company Focused on …
ƒTQTÕzHDA ) çï aîÉl~ýyúrRy–Ì‚ã-†˜ è ÂbÂ’°Ùxþÿ)Y’m ·%cLÿwÌå: ¶ô=×—Óëø·5© Ú ¹Ë²Ì=#$ õƒ‘*ALêñÿïOËÝM*¦LÑ Ûá ¨JŸtÉV÷¾û ÉR! ½À²Ç .Ï°î» ¾$“Œ Öz5; ²CÄmα= uX”ö„¼©¦ÜÔ)¹è©í7u ÇPmwo£€ˆx#&Ëpâ]:†G &0韮·Bs¶xÕ¹ æqo …See details»
Investor Relations - Pharvaris N.V.
Oct 24, 2024 Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. …See details»
Pharvaris - Crunchbase Company Profile & Funding
PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study. The co-founders of Pharvaris …See details»
Careers - Pharvaris
Pharvaris’ mission is to pioneer science for patient choice. If you are looking for a place where your work can have meaning and you can make a difference – Pharvaris is the place for you. …See details»
Pharvaris GmbH – Swiss Biotech
Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. Pharvaris aspires to offer people with all types …See details»
Pharvaris Announces Changes to its Board of Directors
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the …See details»
Pharvaris Company Profile - Office Locations, Competitors, …
Oct 10, 2024 Pharvaris is a clinical-stage company focused on the discovery and development of oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) …See details»
Pharvaris Provides Business Update and Outlines 2024 Strategic
Jan 5, 2024 About Pharvaris Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent …See details»
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial …
Apr 5, 2023 The World Health Organization’s (WHO) International Nonproprietary Names (INN) Expert Committee and the United States Adopted Names (USAN) Council of the American …See details»
Pharvaris - LinkedIn
Pharvaris | 4,679 followers on LinkedIn. Pioneering science for patient choice | Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to …See details»
Pharvaris N.V. (PHVS)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small …See details»
Pharvaris N.V. (PHVS) Stock Price, News, Quote & History - Yahoo …
Find the latest Pharvaris N.V. (PHVS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Pharvaris Announces $80 Million Series C Financing to Advance …
According to HAE International , the global umbrella organization for the world's HAE patient groups, HAE affects from 1:50,000 to 1:10,000 individuals globally, or at ... About Pharvaris …See details»
Pharvaris Reports First Quarter 2021 Financial Results and Provides ...
Pharvaris is developing this formulation to provide sustained exposure of attack-preventing medicine in a convenient, small oral dosage form. PHVS719 is currently in preclinical …See details»
Pharvaris Announces $80 Million Series C Financing to Advance …
Nov 18, 2020 Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema …See details»
Pharvaris shares spike as drug appears to prevent symptoms of …
Dec 6, 2023 “Pharvaris remains committed to resolving the U.S. clinical hold on deucrictibant for the prophylactic treatment of [hereditary angioedema], and we are on track to submit the non …See details»
Clinical Pipeline - B2 Receptor Antagonism - Pharvaris
CHAPTER-1. The CHAPTER-1 study is designed to enroll 30 patients globally with a goal of evaluating proof-of-concept of deucrictibant as an oral prophylaxis against HAE attacks. The …See details»
Pharvaris N.V. (PHVS) Stock Price, Quote & News - Stock Analysis
6 days ago Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops …See details»
Pharvaris price target lowered to $46 from $50 at JMP Securities
4 days ago JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Pharvaris (PHVS) to $46 from $50 and keeps an Outperform rating on the shares as part of a …See details»